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1gG and igA antibodies to Epstein-Barr virus (EBV) 
membrane antigen (MA) were detected in sera from 
96 NPC patients and normal individuals by the indi- 
rect immunofluorescence test. For MA/lgG antibody, 
100% of NPC patients were positive with a GMT of 
I :439.7 and 97.9% of normal individuals were positive 
with a GMT of 1:94.7. In contrast, for MA/lgA anti- 
body, 58.3% of NPC patients were positive with a 
GMT of 1:7.3 and none of the normal individuals were 
positive. There was no difference in the detection of 
antibodies to EBV MA when other P3HR-I or B95-8 
cell lines, differing in their major membrane antigen, 
were used. 
Klein et al. (1966) first demonstrated EBV MA in 
cells from Burkitt lymphoma by the indirect immuno- 
fluorescence test, and then proved that the MA was 
specific to EBV by a direct blocking test (Klein et al.,  
1969). Other studies have shown that EBV MA exists 
on both the EBV envelope and the membrane of cells 
which carry EBV genomes and produce intact EBV 
particles (Sugawara and Osato, 1970; Silvestre et al . ,  
1971). These data indicate that the antibody titer to 
MA correlates well with that of neutralizing antibody 
to EBV (Pearson et al . ,  1970). There are no published 
reports concerning IgA antibody to EBV MA. A hy- 
pothesis links blocking of ADCC with the appearance 
of IgA antibodies mainly directed to VCA or EA 
(Mathew et a l . ,  1981). However, no data have been 
presented on the reactivity of IgG and particularly IgA 
antibodies in sera from NPC patients and normal indi- 
viduals to the membrane antigen by indirect immuno- 
fluorescence tests. 
MATERIAL AND METHODS 
Sera 
normal individuals, and stored at -20°C. 
Indirect immunojluorescence test 
The target cells used for detection of MA/IgG and 
MAiIgA antibodies were P3HR-1 or B95-8 cells. They 
were cultured in RPMI 1640 medium with 20% new- 
born calf serum. 
P3HR-1 or B95-8 cells were activated for 48 hr by 
4 m ~  n-butyrate and 500 ng/ml of croton oil. The 
activated cells were washed 3 times with Hanks' solu- 
tion and adjusted to 1 X lo6 celldml. Then 1 X lo5 cells 
in 100 pl were added to each well of 96-well U-shaped 
hemagglutination plates. The sera were diluted from 
1 : 10 to 1 :640 in 2-fold dilution and then placed in a 
humidified chamber at 37°C for 45 min. After 3 
washes with Hanks' solution, cell smears were pre- 
pared on slides, air-dried and fixed with cold acetone. 
Sera were obtained from 48 NPC patients and 48 
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FIGURE 1 - Comparison of the EBV-MA positive rate in 
P3 HR-I (0) and B95-8 (m) cells. 
FITC-conjugated sheep antibodies diluted 1 : 10 and 
directed to human IgG or IgA were added and the 
slides were kept at 37°C for 30 min. The smears were 
again washed 3 times with 0 . 0 1 ~  PBS, PH 7.6. After 
counter-staining with 0.006% Evans' blue for 10 min, 
they were examined under an Olympus fluorescence 
microscope. Cell membranes stained with a specific 
green color were considered to be positive. The num- 
ber of cells positive for MA was measured with the 
test described above, a mixture of several sera being 
used as first antibody. 
Immunoenzymatic test 
(1979). 
The test was performed as described by Zeng et al. 
RESULTS 
Comparison of the EBV-MA-positivity in P3HR-I and 
895-8 cell lines 
The positivity of the EBV MA in untreated P3HR-1 
and B95-8 cells was 9.1% and 11.2% respectively. 
The numbers increased to 62.1 % and 63.4% respec- 
tively after activation with croton oil and n-butyrate 
for 48 hr. There was no further increase in MA posi- 
tivity after activation for 72 hr and more fragmented 
cells were found (Fig. 1). 
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TABLE I - COMPARISON OF POSITIVITY RATE OF IgG AND IgA ANTIBODIES TO VCA AND MA FROM NPC PATIENTS 
AND NORMAL INDIVIDUALS 
MAIIgG' MAlIgA' VCA/IgA* EAIIg A' 
Number % positivity Number % positivity Number % positivity Number % positivity 
Cases 
NPC 48 48 100 28 58.3 48 100 31 64.6 
Normal 48 47 91.9 0 0 0 0 0 0 
patients 
individuals 
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FIGURE 2 - Comparison of MA/IgG and MA/IgA antibod- 
ies from NPC patients and normal individuals. 
Comparison of the prevalence rate of EBV MAIlgG, 
MA/IgA, VCA/lgA and EA/lgA antibodies in sera from 
NPC patients and normal individuals 
Sera from 48 NPC patients and from 48 normal 
individuals were tested for EBV MAIlgG and MAllgA 
antibodies by the immunofluorescence test, and for 
VCAIIgA and EAIIgA antibodies by the imrnunoen- 
zymatic test. The positivity of the above 4 antibodies 
was 100%, 58.396, 100% and 64.6% respectively, in 
NPC patients, and 97.9%, 0%, 0% and 0% respec- 
tively, in normal individuals (Table I). 
Comparison of the distribution of EBV MA/IgG and 
MA/lgA antibody titers in NPC patients and normal 
individuals 
As shown in Figure 2, the range of the MAIIgG 
antibody titers for NPC patients was from 1:40 to 
1:1,280 with a GMT of 1:439.7, and the range for 
normal individuals was from 1: lO to 1:640 with a 
GMT of 1:94.7. The range of MAlIgA antibody titers 
for NPC patients was from 1 : 10 to 1 : 160 with a GMT 
of 1:7.3; only 52% of the patients had antibody titers 
higher than 1:20, but no such antibodies could be 
found in normal individuals. In most NPC cases the 
VCAJIgA antibody titer was higher than that of MA/ 
IgA antibodies (Fig. 3); this difference was less sig- 
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FIGURE 3 - Relationship between MA/IgA and VCA/IgA 
antibodies in sera from NPC patients. 
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FIGURE 4 - Relationship between MAiIgA and EA/IgA an- 
tibodies in sera from NPC patients. 
DISCUSSION 
It has been shown that the detection of IgA antibody 
to VCA and EA of EBV is of value for the diagnosis 
of NPC (Henle and Henle, 1976; Zeng et al.,  1979a,b; 
1980; 19836). The positivity of MAlIgG antibody was 
very high both in NPC patients and in normal individ- 
uals. Although the GMT of MAIIgG antibody is much 
higher in NPC patients than in normal individuals, this 
test is of no value for the diagnosis of individual cases. 
Of NPC patients, 58.3% had MAIIgA antibody, while 
all normal individuals lacked IgA antibodies to this 
antigen. The situation is similar to that seen with EAI 
IgA antibodies in NPC patients and in normal individ- 
uals (Zeng et al., 1983b), hence detection of MAIIgA 
antibody can be used as a marker for the diagnosis of 
NPC . 
The positivity of MA in P3HR-1 and B95-8 cells 
was similar, although the major membrane glycopro- 
tein differs in both cell lines (Edson and Thorley- 
Lawson, 1983) suggesting that both lines can be used 
as targets for the detection of EBV MAIIgA antibod- 
ies. For a higher expression of MA, cells could be 
activated with croton oil and n-butyrate for 48 hr 
before use. 
Detection of EBV MA/IgA antibody is more spe- 
cific, but not as sensitive for the diagnosis of NPC as 
detection of VCAIIgA antibodies. However, a more 
sensitive technique for the detection of EBV MAIIgA 
antibodies should considerably reduce the false nega- 
tives and give an even better diagnostic value (Jilg and 
Wolf, 1985). 
The predictive value of MA/IgA antibodies for the 
prognosis of patients is under investigation. An eco- 
nomical production of MA, using genetic engineering 
technology, should prove helpful for the development 
of simpler tests which would allow screening of large 
quantities of serum. 
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